Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the sale, the director now owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 29th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.72, for a total value of $76,923.84.
• On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.67, for a total value of $76,351.49.
• On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.22, for a total transaction of $71,200.34.
• On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48.
• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.27, for a total transaction of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.12, for a total value of $81,502.64.

Recursion Pharmaceuticals Trading Down 10.6 %

Shares of RXRX stock opened at $6.18 on Friday. The stock has a market capitalization of $1.74 billion, a P/E ratio of -4.04 and a beta of 0.81. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.89 and a fifty-two week high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a 50 day moving average price of $6.66 and a 200 day moving average price of $7.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue was up 147.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.43) EPS. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the topic of several recent analyst reports. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Jefferies Financial Group dropped their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $9.25.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC purchased a new position in Recursion Pharmaceuticals in the first quarter worth approximately $310,000. Swiss National Bank grew its stake in shares of Recursion Pharmaceuticals by 9.6% during the first quarter. Swiss National Bank now owns 308,500 shares of the company’s stock worth $3,076,000 after purchasing an additional 27,100 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Recursion Pharmaceuticals by 45.2% in the first quarter. Russell Investments Group Ltd. now owns 158,305 shares of the company’s stock valued at $1,578,000 after buying an additional 49,292 shares during the last quarter. ProShare Advisors LLC raised its stake in Recursion Pharmaceuticals by 14.1% in the first quarter. ProShare Advisors LLC now owns 40,949 shares of the company’s stock valued at $408,000 after buying an additional 5,051 shares in the last quarter. Finally, Kingsview Wealth Management LLC purchased a new stake in Recursion Pharmaceuticals during the 1st quarter worth about $240,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.